Insmed Reports Q3 2026 Results & Raises Full-Year Revenue Guidance

Overview

On October 29, 2026, Insmed Incorporated (NASDAQ: INSM) filed a Form 8-K disclosing its financial results for the third quarter ended September 30, 2026, alongside corporate and clinical development updates.

Key Financial Highlights

• Total Revenue: Reported at $524.4 million for the third quarter of 2026.
• BRINSUPRI® (brensocatib): Delivered $400.1 million in global net revenue, representing a 29% increase compared to Q2 2026, driven predominantly by rapid U.S. adoption ($398.1M U.S., $2.0M international).
• ARIKAYCE®: Generated $124.4 million in global net revenue, a 9% year-over-year increase from $114.3 million in Q3 2025, led by strong international growth (+21% YoY to $48.9M).

Full-Year 2026 Guidance Upward Revision

• BRINSUPRI: Raised full-year 2026 guidance to $1.35 billion – $1.40 billion.
• ARIKAYCE: Raised full-year 2026 guidance to $460 million – $470 million.

Commercial & Clinical Pipeline Updates

• BRINSUPRI (Japan): Approved by Japan's MHLW in August 2026 and officially launched in October 2026 for non-cystic fibrosis bronchiectasis (NCFB).
• ARIKAYCE (sNDA): FDA granted Priority Review for the sNDA in MAC lung disease, establishing a PDUFA action date of January 28, 2027. Phase 3 ENCORE data submission planned for Japan's PMDA in Q4 2026.
• TPIP (treprostinil palmitil inhalation powder):
  • PALM-ILD (PH-ILD): Reached >35% enrollment; completion expected in H1 2028.
  • PALM-PAH (PAH): First patient enrolled in July 2026.
  • PALM-PPF (PPF): Phase 3 study initiated in September 2026.
  • IPF: Phase 3 initiation targeted for H1 2027.
• Early Pipeline: Healthy volunteer dosing initiated in Phase 1 for INS1033 (DPP1 inhibitor for RA); enrollment completed in Phase 1 ASCEND study for INS1201 (DMD gene therapy).